ClinicalTrials.gg
CompletedNCT05126784Updated May 29, 2024

AVT03 With Prolia in Healthy Male Subjects

A Phase 1 interventional study of AVT03 and Prolia in Healthy Male Subjects, sponsored by Alvotech Swiss AG. Completed at 4 sites in 3 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
Male
01

Study summary

This study has been designed as a randomized, double-blind, single-dose, parallel-group study in healthy adult male subjects 28 years to 55 years old. The study will assess the PK, PD, safety, tolerability and immunogenicity of AVT03 compared to Prolia when administered as a single SC dose.

Read the detailed description

The study will consist of a 4 week screening period, a 252 day (36 weeks) treatment and assessment period, and an End of Study (EOS) visit on week 36 on Day 252. Subjects will undertake a screening visit between Day -28 and Day -1 to determine their eligibility for the study. On Day 1, eligible subjects will be randomized and will receive a single dose of AVT03 or Prolia as subcutaneous injection.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • Denosumab
  • Healthy Volunteers
03

In context

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects who are 28 to 55 years old, inclusive
  • Have a body weight of 50.0 to 90.0 kg (inclusive) and (BMI) of 17.0 to 32.0 kg/m2 (inclusive)at Screening and Day -1
  • Medical history without evidence of a disorder, condition, or disease that, in the opinion of the Investigator, would pose a risk to subject safety

Exclusion criteria

Exclusion Criteria:

  • Any evidence of pathology, especially prior diagnosis of bone disease, or any uncontrolled condition that will affect bone metabolism (such as, but not limited to osteoporosis, osteogenesis imperfecta, hyperparathyroidism, hyperthyroidism, hypothyroidism, osteomalacia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, current flare-up of osteoarthritis and/or gout, active , renal disease, Paget's disease of the bone, recent bone fracture [within 6 months], and malabsorption syndrome)
  • Have osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery) within 6 months prior to Day 1 or intend to undergo such procedures during the study period, poor oral hygiene, periodontal, and/or pre existing dental disease
  • Have bone fractures within 6 months prior to Day -1.
  • Have a history of immunodeficiency
  • Those with skin allergies, or are susceptible to autoinflammatory skin disorders, or prone to the development of allergic skin inflammation
  • Abnormal serum calcium: current hypocalcemia or hypercalcemia at Screening. Serum calcium levels must be within reference ranges.
  • Known vitamin D deficiency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    AVT03 Arm

    AVT03 (denosumab) is the proposed biosimilar for Prolia (denosumab). Subjects in this arm will receive a single 60mg dose of AVT03 (denosumab) as a subcutaneous injection.

    Biological: AVT03

  • Active comparator
    Prolia Arm

    Prolia(denosumab) is the proposed comparator for AVT03 (denosumab). Subjects in this arm will receive a single 60mg dose of Prolia (denosumab) as a subcutaneous injection.

    Biological: Prolia

Interventions

  • BiologicalAVT03

    AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection

    Also known as: AVT03, Biosimilar Denosumab

  • BiologicalDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prolia (denosumab) will be given as single subcutaneous injection

    Also known as: Denosumab

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve (AUC0-last) from day 0 to day 252

    Venous blood samples will be collected for measurement of Area under serum concentration-time curve (AUC 0-t) AVT03 and Prolia

    Time frame: Day 1(week 1) to Day 252 (week 36)

  2. Area under the serum concentration-time curve (AUC0-inf) from day 0 to day 252

    Venous blood samples will be collected for measurement of CTX-1 serum biomarker for AVT03 and Prolia.

    Time frame: Time Frame: Day 1(week 1) to Day 252 (week 36)]

  3. Maximum serum concentration Cmax from day 0 to day 252

    Venous blood samples will be collected for measurement of maximum serum concentration (Cmax) of AVT03 and Prolia.

    Time frame: Day 1(week 1) to Day 252 (week 36)

Secondary outcomes

  1. PD_AUCE0 for CTX-1 (% inhibition)

    Venous blood samples will be collected for measurement of serum concentration of AVT03 and Prolia

    Time frame: Day 1(week 1) to Day 252 (week 36)

  2. PK area under the concentration-time curve (AUC0-24) from Day 0 to Day 252

    Venous blood samples will be collected for measurement of serum concentration of AVT03 and Prolia

    Time frame: Day 1(week 1) to Day 162 (week 24)]

  3. Safety incidence, nature and severity of adverse events

    Time frame: Screening to Day 252 (week 36)

  4. Immunogenicity presence and titers of ADAs and presence of nAbs against AVT03 and Prolia

    Venous blood samples will be collected for measurement of antidrug-antibodies against of AVT03 and Prolia

    Time frame: Time Frame: Day 1(week 1) to Day 252 (week 36)

07

Study locations

4 sites
  • Nucleus Network
    Herston, Australia
  • NZCR Christchurch
    Christchurch, Christchuch, New Zealand
  • NZCR Auckland
    Auckland, New Zealand
  • Farmovs
    Bloemfontein, South Africa
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Oct 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2021
First posted
Nov 19, 2021
StartActual
Jun 29, 2022
Primary completionActual
Oct 16, 2023
CompletionActual
Oct 16, 2023
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05126784
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Jun 29, 2022
Primary completion
Oct 16, 2023
Completion
Oct 16, 2023
Last update
May 29, 2024

Study contacts

Felicitas Bullo
study director · Alvotech

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVT03

Start the discussion